Key result
Coronary artery disease in the transplanted heart is driven by immune-mediated inflammation and endothelial injury, with retransplantation remaining the only definitive but controversial treatment.
Cardiac allograft vasculopathy is driven by complex immune and inflammatory responses, with limited treatment options beyond ethically controversial retransplantation.
Answers are grounded in this paper and cite their sources.
May prompt enhanced post-transplant immunomodulation; leaves open whether targeted therapies can delay retransplantation.
Coronary artery disease in the transplanted heart limits the long-term success of cardiac transplantation. Intravascular ultrasound studies reveal a dual morphology with donor-transmitted and de novo plaques. Coronary vasomotor dysfunction may occur independently of morphological alterations. The disease is characterized by the interaction of activated T lymphocytes with cytokines and donor epicardial and microvascular endothelium. Various noxious stimuli contribute to the continuing inflammatory response. Consequently, adhesion molecule expression is upregulated, leukocytes migrate into the allograft, thrombocytes accumulate, and growth factors are expressed, finally resulting in functional and morphological chronic allograft lesions. Blocking the activation of T cells, CD4+ cytokines, and adhesion molecules may prevent endothelial injury and subsequent intimal thickening. Strategies to decrease the formation of anti-endothelial and anti-HLA-DR antibodies may also be protective, as may antiproliferative drugs, augmentation of endogenous nitric oxide bioactivity, and new immunosuppressive regimens. Revascularization procedures have a limited role in treating significant focal lesions. Retransplantation, the only definitive treatment, remains ethically controversial.
No takes yet. Share an insight, caveat, or question.
Weis et al. (2000) conducted a review in Coronary artery disease in the transplanted heart. Coronary artery disease in the transplanted heart is driven by immune-mediated inflammation and endothelial injury, with retransplantation remaining the only definitive but controversial treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: